ATE180261T1 - Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen - Google Patents

Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen

Info

Publication number
ATE180261T1
ATE180261T1 AT91903010T AT91903010T ATE180261T1 AT E180261 T1 ATE180261 T1 AT E180261T1 AT 91903010 T AT91903010 T AT 91903010T AT 91903010 T AT91903010 T AT 91903010T AT E180261 T1 ATE180261 T1 AT E180261T1
Authority
AT
Austria
Prior art keywords
proteins
pharmaceutical
human lymphocytes
dna coding
biological uses
Prior art date
Application number
AT91903010T
Other languages
English (en)
Inventor
Thierry Hercend
Frederic Triebel
Original Assignee
Inst Nat Sante Rech Med
Roussy Inst Gustave
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Roussy Inst Gustave filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE180261T1 publication Critical patent/ATE180261T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91903010T 1990-01-08 1991-01-08 Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen ATE180261T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9000126A FR2656800B1 (fr) 1990-01-08 1990-01-08 Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.

Publications (1)

Publication Number Publication Date
ATE180261T1 true ATE180261T1 (de) 1999-06-15

Family

ID=9392569

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91903010T ATE180261T1 (de) 1990-01-08 1991-01-08 Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen

Country Status (13)

Country Link
US (2) US5773578A (de)
EP (1) EP0510079B1 (de)
JP (1) JP2997053B2 (de)
AT (1) ATE180261T1 (de)
DE (1) DE69131249T2 (de)
DK (1) DK0510079T3 (de)
ES (1) ES2134770T3 (de)
FR (1) FR2656800B1 (de)
GR (1) GR3030811T3 (de)
IL (1) IL96907A (de)
MX (1) MX9203379A (de)
WO (1) WO1991010682A1 (de)
ZA (1) ZA91134B (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316920A (en) * 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
AU755030B2 (en) * 1994-05-06 2002-11-28 Institut Gustave Roussy LAG-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody
CA2189657C (fr) * 1994-05-06 2002-03-12 Florence Faure Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
US6197524B1 (en) * 1995-07-21 2001-03-06 Institute National De La Sante Et De La Recherche Medicale Methods for detecting, identifying, isolating, and selectively labelling and targeting TH1 lymphocyte by means of the LAG-3 protein
PT941329E (pt) * 1996-11-29 2004-11-30 Applied Research Systems Metodo para prevenir a rejeicao de enxertos em transplantacao e para produzir uma celula-hospedeiro para terapia genetica universal utilizando activacao de linfocitos (lag-3)
EP0900841A1 (de) * 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Spleissvarianten von LAG-3
EP0893507A1 (de) 1997-07-25 1999-01-27 Institut Gustave Roussy Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs
WO2000037639A2 (en) * 1998-12-18 2000-06-29 Incyte Pharmaceuticals, Inc. Lymphocytic membrane proteins
SE0103423D0 (sv) * 2001-10-12 2001-10-12 Astrazeneca Ab Polymorphism
EP1575480A4 (de) * 2002-02-22 2008-08-06 Genentech Inc Zusammensetzungen und verfahren zur behandlung von immunbedingten erkrankungen
PL1897548T5 (pl) 2003-02-28 2025-03-17 The Johns Hopkins University Regulacja komórek T
KR100808925B1 (ko) 2006-09-29 2008-03-03 고려대학교 산학협력단 돼지 ｌａｇ-3 융합 이뮤노글로블린
EP2044949A1 (de) * 2007-10-05 2009-04-08 Immutep Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
JP6595458B2 (ja) 2013-09-20 2019-10-23 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
RU2696312C2 (ru) 2014-07-16 2019-08-01 Трансген Са Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
ES2833425T3 (es) 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
HUE068868T2 (hu) 2015-07-30 2025-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
IL260021B (en) 2015-12-14 2022-09-01 Macrogenics Inc Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
US11045547B2 (en) 2015-12-16 2021-06-29 Merck Sharp & Dohme Corp. Anti-LAG3 antibodies and antigen-binding fragments
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
EA201991673A1 (ru) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
EP4286009A3 (de) 2017-04-21 2024-04-03 Sillajen, Inc. Kombinationstherapie aus onkolytischem vacciniavirus und checkpoint-inhibitor
ES2965352T3 (es) 2017-05-30 2024-04-12 Bristol Myers Squibb Co Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3)
CN110678200B (zh) 2017-05-30 2024-05-17 百时美施贵宝公司 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
CN118388628A (zh) 2019-03-29 2024-07-26 居里研究所 具有经修饰的生物活性的白介素-2变体
EP3969040A1 (de) 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Kombination von pd-1-inhibitoren und lag-3-inhibitoren zur erhöhung der wirksamkeit bei der behandlung von krebs
WO2021078910A1 (en) 2019-10-22 2021-04-29 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
EP3824954A1 (de) 2019-11-22 2021-05-26 Centre National de la Recherche Scientifique Vorrichtung, einrichtung und verfahren zur ministrahl-strahlentherapie
WO2021224186A1 (en) 2020-05-04 2021-11-11 Institut Curie New pyridine derivatives as radiosensitizers
EP4153628A1 (de) 2020-05-20 2023-03-29 Institut Curie Einzeldomänenantikörper und deren verwendung in krebstherapien
WO2022079270A1 (en) 2020-10-16 2022-04-21 Université D'aix-Marseille Anti-gpc4 single domain antibodies
CA3196243A1 (en) 2020-10-20 2022-04-28 Angela Marinetti Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
KR20230093282A (ko) 2020-10-23 2023-06-27 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 lag-3 길항제 요법
US20230416196A1 (en) 2020-11-18 2023-12-28 Institut Curie Dimer of biguanidines and their therapeutic uses
US20240317890A1 (en) 2021-01-14 2024-09-26 Institut Curie Her2 single domain antibodies variants and cars thereof
WO2022189618A1 (en) 2021-03-12 2022-09-15 Institut Curie Nitrogen-containing heterocycles as radiosensitizers
EP4337763A1 (de) 2021-05-10 2024-03-20 Institut Curie Verfahren zur behandlung von krebs, entzündlichen erkrankungen und autoimmunerkrankungen
CA3227880A1 (en) 2021-08-05 2023-02-09 Marios SOTIROPOULOS Scanning dynamic device for minibeams production
US20240316061A1 (en) 2021-09-17 2024-09-26 Institut Curie Bet inhibitors for treating pab1 deficient cancer
WO2023089032A1 (en) 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
US20250302930A1 (en) 2022-03-24 2025-10-02 Institut Curie Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
EP4499677A1 (de) 2022-03-31 2025-02-05 Institut Curie Modifiziertes rela-protein zur induktion der interferonexpression und manipulierte immunzellen mit verbesserter interferonexpression
US20250241949A1 (en) 2022-04-07 2025-07-31 Institut Curie Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy
WO2023194607A1 (en) 2022-04-07 2023-10-12 Institut Curie Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy
WO2024068617A1 (en) 2022-09-26 2024-04-04 Institut Curie Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy
EP4680342A1 (de) 2023-03-13 2026-01-21 Regeneron Pharmaceuticals, Inc. Kombination von pd-1-inhibitoren und lag-3-inhibitoren zur verbesserten wirksamkeit bei der behandlung von melanom
EP4683630A1 (de) 2023-03-21 2026-01-28 Institut Curie Vps4b-inhibitor zur verwendung in verfahren zur behandlung von hrd-krebs
WO2024194673A1 (en) 2023-03-21 2024-09-26 Institut Curie Methods for the treatment of dedifferentiated liposarcoma
WO2024194402A1 (en) 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
EP4695290A1 (de) 2023-04-13 2026-02-18 Institut Curie Verfahren zur behandlung von akuter lymphoblastischer t-zell-leukämie
WO2025068393A1 (en) 2023-09-27 2025-04-03 Institut Curie Methods for the treatment of fibrotic related diseases
AU2024379466A1 (en) 2023-11-15 2026-04-23 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
EP4574165A1 (de) 2023-12-21 2025-06-25 Egle Therapeutics Immunozytokine zur krebsbehandlung
WO2025133175A1 (en) 2023-12-21 2025-06-26 Egle Therapeutics Immunocytokine for cancer treatment
WO2025158077A1 (en) 2024-01-26 2025-07-31 Institut Curie Lipid degraders to trigger ferroptosis in cancer
WO2025202450A1 (en) 2024-03-28 2025-10-02 Institut Curie Myeloid cells modified by cytokine chimeric receptor and uses thereof
EP4624494A1 (de) 2024-03-29 2025-10-01 Institut Curie Her2-einzeldomänenantikörper und verwendungen davon
WO2025210252A1 (en) 2024-04-05 2025-10-09 Institut Curie Modulators of fam118b protein for use in therapy
WO2026017820A1 (en) 2024-07-18 2026-01-22 Egle Therapeutics Fusion protein for cancer treatment
EP4681780A1 (de) 2024-07-18 2026-01-21 Egle Therapeutics Immunozytokine zur krebsbehandlung
WO2026035866A1 (en) 2024-08-07 2026-02-12 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor
EP4707296A1 (de) 2024-09-05 2026-03-11 Egle Therapeutics Interleukin-2-varianten mit modifizierter biologischer aktivität
EP4707295A1 (de) 2024-09-05 2026-03-11 Egle Therapeutics Interleukin-2-varianten mit modifizierter biologischer aktivität

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV
US4994369A (en) * 1987-12-15 1991-02-19 The Board Of Trustees Of The Leland Stanford Jr. Univ. T-cell activation related gene
US5001230A (en) * 1988-02-18 1991-03-19 Schering Corporation T cell activation markers

Also Published As

Publication number Publication date
IL96907A (en) 1998-10-30
US5874250A (en) 1999-02-23
ZA91134B (en) 1992-08-26
FR2656800A1 (fr) 1991-07-12
WO1991010682A1 (fr) 1991-07-25
DE69131249T2 (de) 1999-12-30
IL96907A0 (en) 1992-03-29
JP2997053B2 (ja) 2000-01-11
MX9203379A (es) 1992-09-01
EP0510079B1 (de) 1999-05-19
FR2656800B1 (fr) 1992-05-15
JPH05503520A (ja) 1993-06-10
DK0510079T3 (da) 1999-11-29
DE69131249D1 (de) 1999-06-24
EP0510079A1 (de) 1992-10-28
ES2134770T3 (es) 1999-10-16
US5773578A (en) 1998-06-30
GR3030811T3 (en) 1999-11-30

Similar Documents

Publication Publication Date Title
ATE180261T1 (de) Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen
ES2142953T3 (es) Factor de crecimiento y diferenciacion de la familia del tgf-beta.
DE69016426D1 (de) Biologische klappenprothese.
FI963101A7 (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoo n, joissa seerumin interleukiini-6-taso on kohonnut
ITTO950367A0 (it) Proteine di prrsv ricombinanti, corredi diagnostici e vaccini contenenti tali proteine di prrsv ricombinanti.
AU3310595A (en) Compositions and methods for identifying biologically active molecules
NO971875D0 (no) Cathepsin 02 protease
NO891805D0 (no) Flertrinns biologisk renseanlegg.
DE69728897D1 (de) Saeugetierchemokine
NO883418L (no) Biologisk dekkskive.
EP0477200A4 (de) Reinigung von proteinen mittels ctap-iii schmelzvorgänge.
DE69836333D1 (de) Neisseria lactoferrin-bindendes protein
ATE278781T1 (de) Tioredioxine h aus zwig und hart-weizen und ähnliche proteine, diese kodierende dna-fragmente und verfahren zu ihrer herstellung
DE68912536D1 (de) Flüssiges Nahrungsmittel zur Proteinzuführung.
FI902803A7 (fi) DNA-sekvenssi, joka koodaa a-amylaasi-pullulanaasientsyymiä
PT676413E (pt) Proteina de ligacao a interferoes alfa/beta, sua preparacao e utilizacao
AU4981093A (en) Nucleotide sequences coding for cryptosporidium proteins, polypeptides coded by said sequences and kits for the use thereof
NO905496D0 (no) Biologisk forenelige, stoff-spesifikke reagenser til behandling av fysiologiske vaesker.
FI880412A7 (fi) Biologista vastetta muuntava aine.
TR26931A (tr) Lak koagülasyonunda molipten bilesiklerinin kullanilmasi.
EP0780472A3 (de) Stress Proteine
DE3880486D1 (de) Aspirator zur aufnahme von koerperfluessigkeiten.
FI885025A0 (fi) Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning.
ATE309371T1 (de) Protein mit dnase-aktivität
RU95114858A (ru) Новый пептидный фрагмент, обладающий биологической активностью инсулина

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee